Published online Aug 27, 2020. doi: 10.4254/wjh.v12.i8.506
Peer-review started: April 13, 2020
First decision: April 29, 2020
Revised: July 9, 2020
Accepted: July 26, 2020
Article in press: July 26, 2020
Published online: August 27, 2020
Core tip: The Hispanic population in the United States is disproportionately affected by non-alcoholic fatty liver disease (NAFLD). Currently, there is no Food and Drug Administration approved treatment for this disease, but several clinical trials are investigating new potential therapies. This study evaluates the inclusion of race and ethnicity in the enrollment of these trials. In a systemic review and meta-analysis of clinical trials for treatment of NAFLD, 44% of eligible trials reported data on race and ethnicity. Despite a high burden of disease, Hispanic participation remained low. Future targeted interventions must take place to increase the enrollment of diverse and representative study populations in clinical trials.